Gritstone bio Inc. (GRTS)
Gritstone bio Statistics
Share Statistics
Gritstone bio has 118.11M shares outstanding. The number of shares has increased by 8.79% in one year.
| Shares Outstanding | 118.11M |
| Shares Change (YoY) | 8.79% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 32.93% |
| Shares Floating | 115.44M |
| Failed to Deliver (FTD) Shares | 12.8K |
| FTD / Avg. Volume | 0.08% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -1.7 and the forward PE ratio is null. Gritstone bio's PEG ratio is 0.53.
| PE Ratio | -1.7 |
| Forward PE | n/a |
| PS Ratio | 177.07 |
| Forward PS | null |
| PB Ratio | 4.55 |
| P/FCF Ratio | -1.87 |
| PEG Ratio | 0.53 |
Enterprise Valuation
Gritstone bio has an Enterprise Value (EV) of 275.17M.
| EV / Sales | 206.74 |
| EV / EBITDA | -2.17 |
| EV / EBIT | -2.26 |
| EV / FCF | -2.18 |
Financial Position
The company has a current ratio of 3.2, with a Debt / Equity ratio of 0.91.
| Current Ratio | 3.2 |
| Quick Ratio | 3.2 |
| Debt / Equity | 0.91 |
| Debt / EBITDA | -0.83 |
| Debt / FCF | -0.83 |
| Interest Coverage | -38.31 |
Financial Efficiency
Return on Equity is -267.1% and Return on Invested Capital is -164.74%.
| Return on Equity | -267.1% |
| Return on Assets | -77.9% |
| Return on Invested Capital | -164.74% |
| Revenue Per Employee | $5.76K |
| Profits Per Employee | $-599.52K |
| Employee Count | 231 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 7.42M |
| Effective Tax Rate | -5.36% |
Stock Price Statistics
The stock price has increased by -95.98% in the last 52 weeks. The beta is 0.5, so Gritstone bio's price volatility has been higher than the market average.
| Beta | 0.5 |
| 52-Week Price Change | -95.98% |
| 50-Day Moving Average | 0.22 |
| 200-Day Moving Average | 0.91 |
| Relative Strength Index (RSI) | 26.36 |
| Average Volume (20 Days) | 17.01M |
Income Statement
In the last 12 months, Gritstone bio had revenue of 1.33M and earned -138.49M in profits. Earnings per share was -1.2.
| Revenue | 1.33M |
| Gross Profit | -6.26M |
| Operating Income | -154.63M |
| Net Income | -138.49M |
| EBITDA | -126.86M |
| EBIT | -134.45M |
| Earnings Per Share (EPS) | -1.2 |
Balance Sheet
The company has 65.28M in cash and 104.78M in debt, giving a net cash position of -39.49M.
| Cash & Cash Equivalents | 65.28M |
| Total Debt | 104.78M |
| Net Cash | -39.49M |
| Retained Earnings | -659.56M |
| Total Assets | 142.54M |
| Working Capital | 36.81M |
Cash Flow
In the last 12 months, operating cash flow was -121.65M and capital expenditures -4.57M, giving a free cash flow of -126.22M.
| Operating Cash Flow | -121.65M |
| Capital Expenditures | -4.57M |
| Free Cash Flow | -126.22M |
| FCF Per Share | -1.09 |
Margins
Gross margin is -470.32%, with operating and profit margins of -11617.88% and -10404.96%.
| Gross Margin | -470.32% |
| Operating Margin | -11617.88% |
| Pretax Margin | -10404.96% |
| Profit Margin | -10404.96% |
| EBITDA Margin | -9531.4% |
| EBIT Margin | -11617.88% |
| FCF Margin | -9483.1% |
Dividends & Yields
GRTS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -58.76% |
| FCF Yield | -53.56% |
Analyst Forecast
The average price target for GRTS is $0.75, which is 2400% higher than the current price. The consensus rating is "Hold".
| Price Target | $0.75 |
| Price Target Difference | 2400% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -9.73 |
| Piotroski F-Score | 1 |